Fig. 5

Survival of patients with elevated levels of JAG2, AURKA, PGK1, and HPRT1. We plotted the survival of patients with the highest 20% expression of each respective biomarker (red line) and compared them to the patients with the lowest 20% expression (blue line) over the course of 100 months. We found no statistically significant difference in survival with regards to high and low expression of PGK1 or JAG2, but found significant decreases in survival in patients with an elevation of AURKA (p-value < 0.0001) and HPRT1 (p-value = 0.041)